Crossmark

First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study

Crossref DOI link: https://doi.org/10.1016/j.artere.2020.11.001

Published Print: 2020-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Barrios, Vivencio

Escobar, Carlos

Arrarte, Vicente

García, Eusebio

Fernández, María Rosa

Rincón, Luis Miguel

Roldán, Cecilia
Funding

Funding for this research was provided by:

Amgen España
License Information

Text and Data Mining valid from 2020-11-01
More Information

This article is maintained by: Elsevier

Article Title: First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study

Journal Title: Clínica e Investigación en Arteriosclerosis (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.artere.2020.11.001

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.arteri.2020.05.002

Content Type: article

Copyright: © 2020 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Arteriosclerosis.

Document is current

Any future updates will be listed below